Inotiv

NOTVPre-clinical

West Lafayette, United StatesFounded 1974inotiv.com

Inotiv operates as a full-service CRO and research model provider, offering a wide array of services including general and genetic toxicology, DMPK, safety pharmacology, histology, pathology, and bioanalysis. Founded in 1974, the company leverages its expertise across ten major therapeutic areas to support clients in de-risking and accelerating their drug development pipelines. As a publicly traded company, Inotiv focuses on delivering integrated solutions that combine scientific rigor with operational efficiency.

Market Cap

$285.5M

Founded

1974

NOTV · Stock Price

USD 8.30+3.61 (+76.97%)

Historical price data

AI Company Overview

Technology Platform

Inotiv operates as an integrated service platform, combining a comprehensive portfolio of nonclinical CRO services (toxicology, DMPK, pathology) with one of the industry's broadest offerings of research models and related products (GEMS, Teklad diets, surgical models).

Pipeline Snapshot

1 drug in pipeline

Drug	Indication	Stage
Spinosad Topical	Scabies	Approved

Funding History

Total raised: $156M

Debt$150MMidCap FinancialNov 15, 2021

IPO$6MUndisclosedJun 15, 1997

Opportunities

Growth is driven by increasing biopharma R&D outsourcing, demand for integrated service providers, and the need for specialized expertise in complex therapeutic areas and novel modalities like Antibody Drug Conjugates (ADCs).

The company's broad, one-stop-shop portfolio is a key differentiator in a fragmented market.

Risk Factors

Key risks include recent operating losses, a disclosed cybersecurity incident, intense competition from larger CROs, regulatory compliance across multiple agencies, sensitivity to biopharma funding cycles, and potential reputational issues related to animal research.

Competitive Landscape

Inotiv competes with large global CROs like Charles River Laboratories and Labcorp, as well as specialty CROs and research model suppliers. Its differentiation lies in the unique integration of a vast research model portfolio with a full suite of discovery and development services, coupled with deep therapeutic area expertise.